NUDT15 and acute lymphoblastic leukemia: The clinical relevance of this compound metabolizer phenotype is highlighted in a study on Brazilian patients with ALL, which found that 0.9% of the cohort were heterozygous carriers for both NUDT15 and TPMT non-function alleles.